Annual Reports in Medicinal Chemistry, Vol. 43

Key Features

• covers findings related to cardiovascular, inflammation, and pulmonary diseases
• examines issues in oncology, from mTor inhibitors to drug targets
• incorporates up-to-date information on drug design and discovery, including delivery to market

Readership: medicinal, pharmaceutical, and organic chemists

Table of Contents

Part I. Central Nervous System Diseases ¨C ROBICHAUD Chapter 1 Recent Advances in Corticotropin Releasing Factor Receptor Antagonists Carolyn D. Dzierba; Richard A. Hartz; Joanne J. Bronson Chapter 2 Recent Advances on the 5-HT5A, 5-HT6 and 5-HT7 Receptors Brock T. Shireman, Pascal Bonaventure and Nicholas I. Carruthers Chapter 3 Recent Advances in Voltage Gated Sodium Channel Blockers: Therapeutic Potential as Drug Targets in the CNS Andreas Termin, Esther Martinborough and Dean Wilson Chapter 4 Medication Development for the Treatment of Substance Abuse Brian Fulton Part II. Cardiovascular and Metabolic Diseases - STAMFORD Chapter 5 GPR40 (FFAR1) Modulators Julio C. Medina and Jonathan B. Houze Chapter 6 Rho-Kinase Inhibitors for Cardiovascular Disease Robert A. Stavenger Chapter 7 LXR Agonists for the Treatment of Atherosclerosis - Recent Highlights Jonathan Bennett, Andrew Cooke, Heather J. McKinnon and Olaf Nimz Chapter 8 Glucagon Receptor Antagonists for Type II Diabetes DuaneE. DeMong, Michael W. Miller and Jean Lachowicz Part III. Inflammation / Pulmonary / GI ¨C BARRISH Chapter 9 Advances Towards Dissociated Non-Steroidal Glucocorticoid Receptor Agonists John Regan, Hossein Razavi, David Thomson Chapter 10 Advances in the Discovery of IkB Kinase Inhibitors William J. Pitts and James Kempson Chapter 11 Protease Inhibitors for the Potential Treatment of Chronic Obstructive Pulmonary Disease and Asthma Weimin Liu and Eugene Hickey Part IV. Oncology - MYLES Chapter 12 mTor Inhibitors in Oncology Jeroen Verheijen, Ker Yu and Arie Zask Chapter 13 Oncology Drug Targets in the Sphingomyelin Signaling Path Bill Garland, Amy Cavalli and Genevi¨¨ve Hansen Part V. Infectious Diseases - Primeau Chapter 14 Inhibitors of Respiratory Syncytial Virus Malcolm Carter and G. Stuart Cockerill Chapter 15 Recent Developments in ¦Â-Lactamases and Inhibitors Tarek S. Mansour, Patricia A. Bradford and Aranapakam M. Venkatesan Chapter 16 Recent Development in the Treatment of Clostridium Difficile Associated Disease (CDAD) Xicheng Sun, Joseph Guiles and Nebojsa Janjic Chapter 17 Recent Advances in the Discovery of Hybrid Antibacterial Agents Mike Barbachyn Part VI. Topics in Biology - LOWE Chapter 18 Recent Renaissance of Prostaglandin Research Robert Burk Chapter 19 Human Exposure and Dose Projections Punit H. Marathe, Christine Huang and A. David Rodrigues Chapter 20 Modeling Networks of Glycolysis, Overall Energy Metabolism and Drug Metabolism under a Systems Biology Approach Zoltan Sarnyai and Laszlo G. Boros Part VII. Topics in Drug Design and Discovery ¨C DESAI Chapter 21 Contrasting the Gastrointestinal Tracts of Mammals: Factors that Influence Absorption John DeSesso and Amy Lavin Williams Chapter 22 The Emerging Utility of Co-Crystals in Drug Discovery and Development Nicholas Meanwell Chapter 23 Pregnane X Receptor: Prediction and Attenuation of Human CYP3A4 Enzyme Induction and Drug-Drug Interactions Michael W. Sinz Chapter 24 Formulation in Drug Discovery Robert Strictly Part VIII. To Market, To Market Chapter 25 To Market, To Market - 2007 Shridhar Hegde and Michelle Schmidt

Author Information

Edited by John E. Macor, Neuroscience Discovery Chemistry, Bristol-Myers Squibb, USA